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Background-—Only a few studies have systematically evaluated ﬂuoroscopy data of electrophysiological and device implantation
procedures. Aims of this study were to quantify ionizing radiation exposure for electrophysiological/device implantation
procedures in a large series of patients and to analyze the x-ray exposure trend over years and radiation exposure in patients
undergoing atrial ﬁbrillation ablation considering different technical aspects.
Methods and Results-—We performed a retrospective analysis of all electrophysiological/device implantation procedures
performed during the past 7 years in a modern, large-volume laboratory. We reported complete ﬂuoroscopy data on 8150
electrophysiological/device implantation procedures (6095 electrophysiological and 2055 device implantation procedures); for
each type of procedure, effective dose and lifetime attributable risk of cancer incidence and mortality were calculated. Over the
7-year period, we observed a signiﬁcant trend reduction in ﬂuoroscopy time, dose area product, and effective dose for all
electrophysiological procedures (P<0.001) and a not statistically signiﬁcant trend reduction for device implantation procedures.
Analyzing 2416 atrial ﬁbrillation ablations, we observed a signiﬁcant variability of ﬂuoroscopy time, dose area product and effective
dose among 7 different experienced operators (P<0.0001) and a signiﬁcant reduction of ﬂuoroscopy use over time (P<0.0001) for
all of them. Considering atrial ﬁbrillation ablation techniques, ﬂuoroscopy time was not different (P = 0.74) for radiofrequency
catheter ablation in comparison with cryoablation, though cryoablation was still associated with higher dose area product and
effective dose values (P<0.001).
Conclusions-—Electrophysiological procedures involve a nonnegligible x-ray use, leading to an increased risk of malignancy.
Awareness of radiation-related risk, together with technological advances, can successfully optimize ﬂuoroscopy use. ( J Am Heart
Assoc. 2018;7:e008233. DOI: 10.1161/JAHA.117.008233.)
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O ver the past 20 years, the growing number of electro-physiological (EP) procedures and device implantations
(DIs) has caused increased concern over potential radiation
risk effects.1 Fluoroscopy imaging involves a nonnegligible
exposure to ionizing radiation for both patients and
electrophysiology laboratory personnel, depending on labora-
tory workload and the complexity of the procedures.2 Effects
of exposure to ionizing radiation include deterministic and
stochastic effects. The latter is particularly relevant in young
patients, as a consequence of their higher radiosensitivity and
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longer life span, and in patients undergoing long, complex, or
repeated procedures because of cumulative high radiation
doses.3–8 On the other hand, the total exposure also may lead
to a signiﬁcant cumulative dose and lifelong radiation risk to
the electrophysiology staff.9,10 For this reason, the European
Directives and the International Commission on Radiological
Protection recommend that physicians should be guided by
the diagnostic reference levels for an appropriate use of
radiation.11
Recently, the major cardiovascular societies have pub-
lished recommendations about x-rays use in interventional
cardiology and suggested practical ways to reduce them.12–14
This can be achieved by raising operator awareness, optimiz-
ing the technical settings of the x-ray system, or using a
3-dimensional electroanatomic mapping (EAM) system.
However, to date, there are few data evaluating in a
systematic way ﬂuoroscopy time, dose exposure in terms of
dose area product (DAP), radiation-related risk evaluated by
effective dose (ED) and lifetime attributable risk of cancer
incidence in patients undergoing EP/DI procedures. Further-
more, diagnostic reference levels for EP/DI procedures have
not yet been proposed.
The aims of this study are: (1) to quantify ionizing radiation
exposure for all types of EP/DI procedures in a large series of
patients; (2) to analyze the x-ray exposure trend over the
years, considering that no institutional changes and/or
recommendations about ﬂuoroscopy use were performed
and operators are free to use ﬂuoroscopy according to their
sensitivity; and (3) to analyze radiation exposure in patients
undergoing atrial ﬁbrillation (AF) ablation considering the
ablation technique, redo procedures, preprocedural computed
tomographic (CT) scan and the experience of operators.
Finally, based on our results, we propose and promote the
use of updated diagnostic reference levels for EP/DI
procedures, as they are an important reference for every
electrophysiology laboratory to compare itself with the
present standard.
Methods
This is a retrospective study conducted at the Heart Rhythm
Center at Centro Cardiologico Monzino IRCCS, Milan, Italy.
The Institutional Review Board approved the study. All
patients gave a generic written consent for scientiﬁc
purposes. The data, analytic methods, and study materials
will be made available to other researchers for purposes of
reproducing the results or replicating the procedure. The data
that support the ﬁndings of this study are available from the
corresponding author on request.
The electrophysiology database of our institution was
reviewed to identify all patients who underwent EP and DI
procedures between January 2010 and December 2016.
Electrophysiological procedures included EP studies,
catheter ablation of supraventricular tachycardia, atrial ﬂutter
and atrial tachycardia, AF, premature ventricular contractions,
ventricular tachycardia.
DI included implantation of a permanent pacemaker or
cardioverter-deﬁbrillator and cardiac resynchronization ther-
apy devices.
Demographic, clinical, and procedural data were collected,
including age, sex, type of electrophysiological procedure,
ﬂuoroscopy time, and DAP incurred to the patient. In the case
of atrial ﬁbrillation ablation patients, we also took into
account history of previous AF ablation procedures, ablation
technology used, preprocedural CT scan, and ﬁrst operator’s
experience. Only cases with availability of all clinical, proce-
dural, and ﬂuoroscopic data were included in the study.
All procedures were performed by 12 operators routinely
working at the Center; of these, 7 operators performing at
least 50 AF procedures per year in the past 10 years were
considered experienced AF ablation operators.11 Because our
institution has a cardiology fellowship training program, all
procedures entailed some degree of fellow education involv-
ing catheter manipulation.
During this 7-year period, no institutional changes or
recommendations about ﬂuoroscopy use were made, but
operators, according to their sensitivity and x-ray awareness,
have adapted their method of working.
The procedures were performed in 3 different electrophys-
iology rooms; in all 3 rooms, x-ray imaging was performed
using a GE Innova 2100IQ (General Electric Healthcare) with
total ﬁltration of 3 mCu, and anodic angle of 120°. The
screening ﬂuoroscopy was routinely performed at the factory
low setting of 7.5 pulses per second, pulse length of 6 ms,
ﬁeld of view of 20 cm, energy per frame of 70 to 80 kV, no
collimation, and with the secondary radiation grid in situ.
Clinical Perspective
What Is New?
• Comprehensive ﬂuoroscopy data (ﬂuoroscopy time,
dose-area product, effective dose) for electrophysiological
procedures are reported in a large “real-life” electrophysi-
ological population.
• An assumption for the lifetime attributable risk was
assessed.
• The analysis of the x-ray use in 7 experienced operators
performing AF ablation showed an overall signiﬁcant
difference in ﬂuoroscopy use among them.
What Are the Clinical Implications?
• Awareness and culture of radiation-related risk and techno-
logical advances can successfully optimize ﬂuoroscopy use.
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Because of the necessity of image storing, we stored the last
ﬂuoroscopy image in most cases, while we used angiography
only in selected cases (ie, cryoablation, cardiac resynchro-
nization therapy, and epicardial ventricular tachycardia abla-
tion). When used, angiography images were acquired with the
following settings: 15 pulses per second, pulse length of
7 ms, ﬁeld of view of 20 cm, energy per frame of 90 kV, and
no collimation.
DAP was measured using the inbuilt DAPmeter (DIA-
MENTOR; M4-KDK DAP/Dose Meter, PTW, Freiburg, Ger-
many), and it was expressed in centigray9cm2 (cGy9cm2).
The malignancy risk attributable to radiation exposure
during the electrophysiological procedures was evaluated by
the calculation of the mean ED with the formula: mSv=DAP
(Gy9cm2)90.20 for men, mSv=DAP (Gy9cm2)90.2091.38
for women; 0.40 should be used instead of 0.20 in patients
that are <15 years old.14
Furthermore, an assumption for the lifetime attributable
risk of cancer incidence and mortality was estimated multi-
plying the ED that each patient received with the standardized
Biological Effects of Ionizing Radiation VII conversion factor of
0.0001/mSv.15
Technical Features
All complex electrophysiological procedures (ie, AF or atypical
atrial ﬂutter ablation, ventricular tachycardia or premature
ventricular contraction ablation) were performed using 1 of 2
different nonﬂuoroscopic 3-dimensional electroanatomic map-
ping systems available at our center: CartoTM (Biosense
Webster, CA, USA) or EnSite-NavXTM (Abbott, MN, USA). In
the case of AF ablation, different technologies were routinely
used: manual radiofrequency catheter ablations; cryoablation
(Arctic FrontTM and Arctic Front AdvanceTM; Medtronic, Min-
neapolis, MN, USA); and robotic catheter ablations (Hansen
Medical, Mountain View, CA, USA). An intracardiac echocar-
diogram (AcuNav, Siemens Healthcare, USA; or ViewFlex,
Abbott, Toms River, NJ, USA) was used in all ventricular
tachycardia ablations and in selected cases of AF ablation.
For supraventricular tachycardia, a 3-dimensional elec-
troanatomic mapping system was used only in selected cases
in order to obtain a minimal ﬂuoroscopic approach. All other
procedures were performed with ﬂuoroscopy only.
Statistical Analysis
All outcome measures were skewed by continuous variables;
therefore, nonparametric tools were used. Standard descrip-
tive statistics were used to summarize the data and expressed
as median (with range or interquartile range).
Differences in measures of radiation exposure across
procedural and interventional types were tested using the
Kruskal-Wallis test (nonparametric analog of ANOVA), and then
further compared after adjustment using linear regression.
Correlations between variables were determined using
P trends of variation from 2010 to 2016 were assessed by the
analysis of covariance (ANCOVA).
All statistical analyses were performed using SPSS v.22
and SAS 9.4. Statistical signiﬁcance was established a priori
at a 2-tailed P<0.05.
Results
Between January 1, 2010, and December 31, 2016, a total of
7795 EP procedures and 2805 DIs were performed in our
center. All clinical, procedural, and ﬂuoroscopic data were
available on 8150 procedures that constituted the study
population.
Overall study population consisted of 2416 AF ablations
(mean age 6011; 74% male); 468 atrial ﬂutter or atrial
Table 1. Study Population Distribution Over the 7-Year Study Period
2010 2011 2012 2013 2014 2015 2016 7 Years
AF 245 274 290 364 339 442 462 2416
AFl/AT 34 73 49 71 57 96 88 468
SVT 127 128 122 129 136 167 170 979
VT 53 57 43 80 66 82 72 453
PVC 52 40 49 61 71 78 99 450
EPS 151 205 105 185 133 276 274 1329
PM/ICD 102 125 138 248 245 438 447 1743
CRT 10 31 31 38 52 63 87 312
All procedures 774 933 827 1176 1099 1642 1699 8150
AF indicates atrial ﬁbrillation; AFl, atrial ﬂutter; AT, atrial tachycardia; CRT, cardiac resynchronization therapy devices; EPS, electrophysiology studies; ICD, implantable cardioverter
deﬁbrillator; PM, pacemaker; PVC, premature ventricular contractions; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
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tachycardia ablations (mean age 6016; 74% male); 979
supraventricular tachycardia ablations (mean age 4518; 44%
male; 113 procedures were performed according to a minimal
ﬂuoroscopic approach); 453 ventricular tachycardia ablations
(mean age 6116; 89% male); 450 premature ventricular
contraction ablations (mean age 4717; 64% male); 1329 EP
studies (mean age 5419; 69% male); 1743 permanent
pacemaker/cardioverter-deﬁbrillator implantations (mean age
7412; 67% male); and 312 cardiac resynchronization
procedures (mean age 7010; 76% male).
Table 1 summarizes study population distribution over the
7-year study period.
Fluoroscopy exposure data for the study population are
summarized in Table 2. In the same table, the estimated
lifetime attributable cancer risk is calculated. For example, in
our population, a patient who underwent an AF ablation had a
potential increased cancer risk of 0.16% over the base rate
risk; that means that there is potentially an excess of 160
cancers observed in a population of 100 000 treated
patients.
Overall, our ﬂuoroscopy data results were comparable to
ﬂuoroscopy exposure reported in the literature. In Table S1,
we report a brief nonsystematic review of available data
regarding ﬂuoroscopy use and dose, considering only studies
with at least 50 patients and that reported either DAP or ED.
Fluoroscopy Exposure Data Over Time
Fluoroscopy use and radiation exposure data for different
EP/DI procedures were analyzed over time (Table 3). A
ﬂuoroscopy exposure trend was calculated showing a
signiﬁcant reduction (P<0.0001) in ﬂuoroscopy time and
DAP and ED values for AF, atrial ﬂutter/atrial tachycardia,
supraventricular tachycardia, ventricular tachycardia, prema-
ture ventricular contraction ablation, and electrophysiological
studies (ED–electrophysiological studies: P = 0.02), while a
not signiﬁcant consensual reduction in all exposure values
was observed for both permanent pacemaker/cardioverter-
deﬁbrillator and cardiac resynchronization device implanta-
tion procedures.
Fluoroscopy Exposure in AF Ablation Procedure
Analysis according to operators
Seven different experienced electrophysiology operators
(>50 procedures per year in the past 10 years) were
compared in order to evaluate the differences in the use of
x-rays over the course of 7 years. Overall, there was a
signiﬁcant variability (P<0.0001) of ﬂuoroscopy time, DAP,
and ED values among operators (Table 4).
Interestingly, over 7 years of activity, all the operators
signiﬁcantly decreased (P<0.0001) the use of x-rays with Ta
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Table 3. Fluoroscopy Use and Radiation Exposure Over Time
Fluoroscopy Time (Min) DAP (cGy9cm2) Effective Dose (mSv)
AF 2010 45 (32–64) P trend <0.0001
D = 59%
16 213 (9466–26 732) P trend <0.0001
D = 74%
34.0 (19.9–58.2) P trend <0.0001
D = 73%2011 39 (27–51) 13 011 (7673–21 449) 28.3 (16.9–46.4)
2012 28 (20–37) 11 217 (6411–17 197) 24.2 (13.8–37.1)
2013 24 (17–31) 7821 (4750–13 357) 16.9 (10.1–28.2)
2014 20 (14–27) 6565 (3870–10 783) 14.6 (8.4–23.0)
2015 19 (13–27) 5489 (2499–9839) 12.0 (6.0–21.0)
2016 16 (11–22) 3455 (1643–6365) 7.3 (3.6–13.5)
AFl/AT 2010 16 (6–30) P trend <0.0001
D = 38%
5002 (2182–10 312) P trend <0.0001
D = 60%
11.0 (4.4–23.7) P trend <0.0001
D = 63%2011 19 (10–33) 5738 (2310–17 334) 12.8 (5.4–35.0)
2012 17 (10–27) 4526 (2437–8664) 10.9 (5.3–17.9)
2013 14 (8–26) 3651 (1676–6997) 8.2 (3.7–14.4)
2014 16 (9–28) 3865 (2283–10 175) 8.1 (4.8–20.4)
2015 10 (7–18) 2359 (935–5690) 5.0 (2.4–12.2)
2016 9 (5–18) 1554 (790–4355) 3.2 (1.7–8.8)
SVT 2010 15 (8–24) P trend <0.0001
D = 40%
2153 (1147–4215) P trend <0.0001
D = 60%
5.4 (2.8–11.1) P trend <0.0001
D = 60%2011 15 (9–22) 2204 (1245–4516) 5.9 (3.4–12.3)
2012 14 (9–24) 2215 (1235–4960) 5.7 (3.0–11.1)
2013 15 (9–22) 2059 (1187–3959) 5.2 (2.8–9.2)
2014 14 (6–22) 1744 (658–4351) 4.2 (1.6–11.2)
2015 10 (4–19) 1100 (255–3208) 3.0 (0.8–7.5)
2016 8 (3–15) 953 (233–1976) 2.2 (0.6–4.7)
VT 2010 47 (34–63) P trend <0.0001
D = 36%
18 051 (11 583–27 092) P trend <0.0001
D = 61%
38.9 (23.8–55.3) P trend <0.0001
D = 62%2011 37 (27–51) 14 152 (7968–20 724) 28.3 (16.1–41.4)
2012 34 (25–46) 20 524 (11 943–24 932) 41.0 (23.9–49.9)
2013 41 (29–55) 20 085 (10 267–30 973) 41.6 (21.1–62.6)
2014 35 (22–44) 14 675 (7044–23 903) 29.3 (14.7–46.3)
2015 32 (18–49) 9687 (3519–20 334) 19.4 (7.9–41.2)
2016 25 (16–39) 4870 (2633–9341) 10.0 (5.4–18.7)
PVC 2010 23 (13–31) P trend <0.0001
D = 53%
4268 (2477–8822) P trend <0.0001
D = 73%
9.7 (6.2–17.9) P trend <0.0001
D = 71%2011 14 (10–22) 3677 (1895–6410) 8.9 (4.1–17.7)
2012 18 (14–24) 4266 (2034–8504) 9.3 (4.3–17.2)
2013 12 (6–21) 2168 (860–4773) 5.1 (2.1–12.2)
2014 12 (8–21) 3663 (1274–7799) 8.1 (3.1–17.3)
2015 14 (9–22) 2762 (865–6673) 6.0 (1.8–13.6)
2016 8 (5–15) 925 (384–2453) 2.2 (0.9–5.1)
EPS 2010 2 (1–5) P trend 0.001
D = 12%
407 (175–939) P trend <0.0001
D = 23%
1.0 (0.4–2.2) P trend 0.02
D = 54%2011 4 (2–7) 628 (246–1566) 1.5 (0.6–3.7)
2012 2 (1–4) 568 (243–1478) 1.1 (0.5–3.4)
2013 2 (1–5) 354 (153–951) 0.8 (0.4–2.1)
2014 2 (1–4) 332 (165–775) 0.7 (0.4–1.7)
2015 2 (1–4) 272 (122–754) 0.6 (0.3–1.6)
2016 2 (1–4) 210 (80–478) 0.5 (0.2–1.1)
Continued
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ﬂuoroscopy time delta values ranging from 44% to 69%
and DAP delta values ranging from 53% to 77% (Figure 1
and Table 5).
A strong linear relationship (r=+0.71883, P<0.0001)
between ﬂuoroscopy time and radiation dose over time was
observed. Statistically different correlation coefﬁcients were
observed among operators (P<0.001), likely representing
different x-ray system technical settings and utilization among
operators. Table 5 shows x-ray use performance over time of
the 7 experienced electrophysiological operators.
Analysis according to AF ablation technique
We compared ﬂuoroscopy exposure data with 2 different AF
ablation techniques: manual radiofrequency catheter abla-
tions guided by electroanatomic mapping systems and
cryoablation procedures. The rate of manual radiofrequency
catheter ablations guided by electroanatomic mapping sys-
tems and cryoablation procedures signiﬁcantly varied over
time (P<0.01) as cryoablation procedures progressively
increased from 13% of AF ablations in 2010 up to 27% in
2016.
Overall, 1809 (75%) manual radiofrequency catheter abla-
tions guided by electroanatomic mapping systems were
performed, counting for a median ﬂuoroscopy time of 24
(15–36) minutes, a median DAP of 7178 (3668–13 423)
cGy9cm2 and a median ED of 15.7 (79–28.6) mSv. A
cryoablation procedure was performed in 496 (21%) cases,
counting for a median ﬂuoroscopy time of 22 (15–32)
minutes, a median DAP of 7820 (4195–13 853) cGy9cm2,
and a median ED of 16.7 (8.8–29.4) mSv. After statistical
adjustment, the difference in ﬂuoroscopy time was not
signiﬁcant between techniques but signiﬁcantly higher DAP
(P = 0.006) and, consequently, ED (P = 0.005) values were
observed in cryoablation procedures. Over 7 years of activity,
both AF ablation techniques were associated with a signiﬁcant
reduction of ﬂuoroscopy time (P<0.0001), DAP (P<0.0001),
and ED (P<0.0001) (Figure 2).
Preprocedural CT scan
Preprocedural CT scan was performed in 44 of 245 (18%)
patients in 2010, 107 of 274 (39%) patients in 2011, 122 of
290 (42%) patients in 2012, 120 of 364 (33%) patients in
2013, 65 of 339 (19%) patients in 2014, 48 of 442 (11%)
patients in 2015, and 14 of 462 (3%) patients in 2016. CT
scan accounted for an adjunctive ED of 4.172.7 mSv until
2012 and 0.410.04 after 2012.16
Redo AF ablation procedures
We evaluated the rate of AF ablation redo procedures, and
we observed that 21% of patients had previously undergone
≥1 AF ablations, with an average of 1.25 procedures and a
maximum of 5 procedures per patient. In patients
that underwent >1 AF ablation, the radiation dose of each
procedure cumulates, and the overall radiation-related
risk should be considered before performing a redo
procedure.
Table 3. Continued
Fluoroscopy Time (Min) DAP (cGy9cm2) Effective Dose (mSv)
PM/ICD 2010 6 (4–10) P trend ns
D = 11%
781 (414–1783) P trend 0.0029
D = 44%
1.8 (1.0–3.9) P trend 0.0028
D = 43%2011 6 (4–9) 824 (395–1677) 1.8 (0.9–3.7)
2012 5 (3–8) 658 (305–1382) 1.4 (0.7–2.9)
2013 4 (3–7) 570 (261–1253) 1.2 (0.6–2.7)
2014 4 (3–8) 629 (260–1139) 1.4 (0.6–2.4)
2015 3 (2–6) 450 (234–1094) 1.0 (0.5–2.3)
2016 4 (2–6) 450 (231–1022) 1.0 (0.5–2.3)
CRT 2010 25 (16–32) P trend 0.05
D = 19%
6923 (3880–10 770) P trend ns 16.0 (10.7–21.5) P trend ns
2011 23 (14–32) 5239 (2788–9841) 10.5 (6.0–21.2)
2012 17 (12–33) 4152 (2485–6636) 8.3 (5.1–14.7)
2013 15 (10–33) 4108 (2633–6849) 8.3 (5.3–13.7)
2014 15 (10–25) 3259 (1717–6367) 7.0 (3.9–12.8)
2015 19 (13–29) 4800 (1963–10 721) 9.6 (4.6–21.4)
2016 17 (10–27) 3640 (1301–7177) 7.5 (3.5–16.7)
AF indicates atrial ﬁbrillation; AFl, atrial ﬂutter; AT, atrial tachycardia; CRT, cardiac resynchronization therapy devices; DAP, dose area product; EPS, electrophysiology studies; ICD,
implantable cardioverter deﬁbrillator; PM, pacemaker; PVC, premature ventricular contractions; SVT, supraventricular tachycardia; VT, ventricular tachycardia.
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Discussion
Radiofrequency catheter ablation is often the ﬁrst-line therapy
for several types of cardiac arrhythmias, and ﬂuoroscopic
guidance during catheter ablation remains the cornerstone in
electrophysiology laboratories. Therefore, EP/DI procedures
are associated with a nonnegligible radiation risk for both
patients and operators. For this reason, in recent years the
“ALARA” principle for cardiac interventions has been
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Figure 1. Fluoroscopy exposure trend per operator over time.
All 7 experienced operators, over time, signiﬁcantly decreased
ﬂuoroscopy time (A) and patient’s dose exposure (B) during AF
ablation procedures. AF indicates atrial ﬁbrillation; DAP, dose area
product; OP, operator.
Table 5. X-Ray Use Performance Over Time of the 7
Experienced Electrophysiology Operators
Fluoroscopy
Time (Delta, %) DAP (Delta, %) Correlation (r) P Value
Op 1 44% 53% +0.64227 <0.0001
Op 2 55% 77% +0.66011
Op 3 68% 77% +0.70147
Op 4 69% 73% +0.7756
Op 5 60% 73% +0.65333
Op 6 62% 76% +0.75268
Op 7 51% 64% +0.69455
DAP indicates dose area product; Op, operator.
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highlighted, which means using techniques and procedures to
keep x-ray exposure to a level As Low As Reasonably
Achievable. Accordingly, the major cardiovascular associa-
tions have published detailed recommendations about x-ray
use and suggested practical ways to reduce it.1,12–14 Never-
theless, the majority of published studies report only
ﬂuoroscopy time (ie, an indirect measure that cannot be
adequately correlated to the risk associated with x-ray
exposure) and, to date, there are only a few and/or small
studies reporting in detail DAP and ED.
To our knowledge, our study is the ﬁrst published study
performed in a large population reporting comprehensive data
on ﬂuoroscopy exposure and therefore giving an estimate of
the effective risk correlated to the use of x-rays in EP and DI
procedures.
Recently, Voskoboinik and colleagues17 described a
reduction in radiation dose in AF ablation over time in a
large series of patients. The authors related this result to
operator experience, annual case volume, technology evolu-
tion, and recent contact force–sensing catheter technology. In
our experience, evaluating the trend of ﬂuoroscopy data over
7 years, the use of x-rays was signiﬁcantly reduced in most
EP/DI procedures. As highlighted in previous studies, tech-
nology improvement could explain signiﬁcant x-ray reduction
time during more complex procedures.18–21 We observed a
signiﬁcant trend in lowering use of x-ray in all types of
procedures; this may not be attributed only to technology
improvement.
In the workﬂow adaptations in order to reduce radiation
exposure proposed by the European Heart Rhythm Associa-
tion’s Practical Guide,1 the ﬁrst recommendation regards
electrophysiologists’ and catheter laboratory personnel’s
constant awareness. This point is clearly evident in our data.
Considering the analysis of x-ray use by 7 experienced
operators performing AF ablation, we observed an overall
signiﬁcant difference in ﬂuoroscopy use among them. The
analysis of correlation between ﬂuoroscopy time and DAP
reduction over time revealed that reduction in ﬂuoroscopy use
led to a different DAP reduction among operators. These data
can be attributed to several factors such as appropriate use of
ﬂuoroscopy, the operator’s preference for extreme angulated
left anterior oblique in contrast with “reduced” left anterior
oblique or anteroposterior projection, the operator’s prefer-
ence for one ablation technology or another, and so on.
However, over 7 years, all of the operators reduced their
amount of both ﬂuoroscopy time and DAP, showing that the
use of ﬂuoroscopy is not strictly a function of experience and
that the awareness of the harm correlated with x-rays and the
presence of a background in radiation safety are the
cornerstones for reducing radiation exposure in interventional
cardiology.22,23
Looking at ﬂuoroscopy time, DAP, and ED in different
procedures and for different operators, we should note that
ﬂuoroscopy time is only an indirect and incomplete measure
of the radiological exposure. In fact, ﬂuoroscopy time
reduction did not always correspond to a consensual statis-
tically signiﬁcant reduction of DAP; DAP value depends on
patients’ body structure (eg, thoracic impedence) and appro-
priate use of ﬂuoroscopy (eg, detector position, projection
angle, collimation, magniﬁcation, frame-rate). Of note, the
individual radiological risk is a function of patients’ age and
sex. Therefore, the report of ﬂuoroscopy time should not be
considered enough per se and the report of DAP and/or ED
should be encouraged in all centers and studies. Furthermore,
the individual lifetime excess risk of cancer incidence and
mortality is estimated only thanks to the value of procedural
ED.
Considering AF ablation techniques, previous papers24
demonstrated that ﬂuoroscopy time was longer in
Figure 2. Comparison of ﬂuoroscopy time and DAP between
mRFCA and Cryo over time. A, Reduction of ﬂuoroscopy time
associated with mRFCA (D = 56%) and Cryo (D = 67%)
procedures over time. There is no difference between the 2
techniques. B, The radiation dose reduction associated with
mRFCA procedure (D = 78%) and Cryo (D = 80%) procedure
over time. Considering the 7-year interval, DAP values were
signiﬁcantly different between the 2 techniques (P = 0.006). If we
consider only the past 2 years, DAP values were similar between
the 2 techniques (P=ns). Cryo indicates cryoablation; DAP, dose
area product; mRFCA, manual radiofrequency catheter ablation.
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cryoablation than radiofrequency ablation; moreover, data of
dose exposure associated with cyoablation are not available.
In our long-term experience, cryoablation gradually reduced
the procedural ﬂuoroscopy time until it was comparable to
radiofrequency catheter ablation. A similar trend may also be
observed for dose exposure, although, over 7 years, cryoab-
lation is still associated with higher values of DAP and ED
compared to radiofrequency catheter ablation.
When performing an electrophysiological procedure, oper-
ators should always consider that it might not be the only one
performed with the use of x-rays. In fact, patients may be
expected to undergo ≥1 ablation procedure in their lifetime
(average AF ablation procedures: 1.5 in literature,25 1.25 in
our series), and they are often subject to other diagnostic
x-ray examinations (ie, cardiac CT scan, coronary angiography,
percutaneous angioplasty). In our population, a patient
undergoing a rhythm control strategy with a catheter ablation
varies his radiological exposure from a minimum of 3.6 mSv
(one catheter ablation procedure, no preprocedural CT scan,
minimum interquartile range ED value overtime) up to
100 mSv (>1 procedure, preprocedural CT scan, maximum
interquartile range ED value). This results in a nonnegligible
estimated excess risk of cancer malignancy induction ranging
from 36 in 100 000 treated patients up to 1 in 100.
Therefore, x-ray awareness and culture is particularly impor-
tant in all procedures for all operators as well as patients.
Finally, we observed that our ﬂuoroscopic exposure data
were consistent with data from the European recommenda-
tions.14 We acknowledge that there are some studies showing
signiﬁcantly lower x-ray exposure even in complex proce-
dures. However, these data were obtained by designed trials
with selected experienced operators and often by studies
aiming at demonstrating radiation reduction exposure with
different techniques. On the contrary, our data derive from the
“real life” of a training center without any selection of
operators and procedures and where the learning curve of
electrophysiology fellows and the learning curve for the
numerous continuously evolving technologies introduced
should be taken into account. We acknowledge that our
single-center data cannot be a reference, but we suggest that
consensus groups start working on radiation exposure at a
society level with the aim of proposing updated diagnostic
reference levels for electrophysiological procedures. In
Table 6, we propose the values of ﬂuoroscopy time and
DAP diagnostic reference levels according to our population.
Study Limitations
Our study was a retrospective analysis of procedures
performed in the past 7 years; unfortunately, we had incom-
plete ﬂuoroscopic data for some procedures.
Moreover, we did not report patients’ body mass index,
and the estimation of ED was performed with the simpliﬁed
formula suggested by the European Heart Rhythm Associa-
tion’s Practical Guide.1 A more accurate estimation of ED
could have been done with more complex models (ie, Monte
Carlo simulation) that also took into account patients’ height
and weight. In our experience, the simpliﬁed international
formula tends to give slightly lower values than those
calculated with the Monte Carlo code.18 Consequently, our
data may underestimate the real ED and the estimated
lifetime attributable cancer risk.
Finally, in our population, we did not analyze a possible
correlation between ﬂuoroscopy use and procedural success.
The recent paper by Voskoboinik and colleagues17 concluded
that ﬂuoroscopy time was the only statistically signiﬁcant
multivariate predictor of AF recurrence; however, numerous
works have shown that a reduced ﬂuoroscopic approach does
not affect procedural success.18–21
We should also acknowledge that we included data from
operators with signiﬁcantly different experience and from
many procedures that also involved trainees. However, we
think that it could be considered a positive feature of our study
because it gives a picture of the real electrophysiological life.
Conclusions
Electrophysiological procedures involve a nonnegligible use of
x-rays. Awareness of the associated risks is fundamental, and
together with technological improvement, it can successfully
reduce and optimize the use of ﬂuoroscopy. Diagnostic
reference levels are important for every electrophysiology
laboratory to compare itself with the present standard.
Currently, ﬂuoroscopic reference values are derived from
the procedures performed in previous decades. In the past
few years, several papers have shown that growing operator
Table 6. Fluoroscopy Time and DAP DRLs According to Study Population
AF (n=2416) AFl/AT (n=468) SVT (n=979) VT (n=453) PVC (n=450) EPS (n=1329) PM/ICD (n=1743) CRT (n=312)
Fluoroscopy time-DRLs 35 24 21 49 22 5 7 29
DAP-DRLs 13 628 6958 3884 23 429 6178 882 1181 8210
AF indicates atrial ﬁbrillation; AFl, atrial ﬂutter; AT, atrial tachycardia; CRT, cardiac resynchronization therapy devices; DAP, dose area product; DRLs, diagnostic reference levels; EPS,
electrophysiology studies; ICD, implantable cardioverter deﬁbrillator; PM, pacemaker; PVC, premature ventricular contractions; SVT, supraventricular tachycardia; VT, ventricular
tachycardia.
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x-ray awareness and rapid technological advances have led to
a progressive reduction in ﬂuoroscopy use in the electro-
physiology laboratories. In this context, we suggest that
consensus groups start working at a society level with the aim
of proposing updated diagnostic reference levels.
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Table S1. Review of available data regarding fluoroscopy exposure. 
 
TYPE OF 
PROCEDURE 
REFERENCE TYPE OF STUDY NUMBER OF PATIENTS FLUOROSCOPY TIME 
(min)* 
DAP 
(cGycm2)* 
EFFECTIVE DOSE 
(mSv)* 
AF 
Ector J et al.1 Observational 85 83 ± 26 11960 (1390-44630) 25.3 ± 13.8 
Smith IR et al.2 Retrospective 202 43.3 (28.5-58.8) 5330 (3440-7300) 7.4 (4.8-10.2) 
Rogers DP et al.3 Observational Pre DRM 79 
Post DRM 263 
- 6330 ± 5010 
3280 ± 3170 
- 
2.83 
Heidbuchel H et al.4 EHRA practical guide - - - 16.6 (6.6-59.6) 
Pontone G et al.5 Retrospective 200 - - 32.8 ± 23.5 
Jourda F et al.6 Observational RF 75 
CB 75 
21.5 ± 8.5 
25.3 ± 9.9 
4748 ± 2411 
7734 ± 5361 
- 
Squara F et al.7 Observational RF 198 
CB 178 
19.3 ± 8.2 
17.6 ± 11 
4273 ± 2934 
4853 ± 5069 
- 
Schneider R et al.8 Observational Pre DRM 101 
Post DRM 105 
29.9 ± 11.3 
13.3 ± 8.3 
8690 ± 5727 
837 ± 647 
- 
Lee G et al.
9
 Retrospective Pre DRM 1005 
Post DRM 510 
41 (28.8) 
9.5 (9.8) 
357.10 (452.7) 
104.35 (105.0) 
- 
Straube F et al.10 Observational RF 180 
CB 193 
16.0 (13.0–23.0)  
16.0 (11.0–28.0)  
2663 (1646–3958) 
2067 (1426–2593) 
- 
Wynn GJ et al.11 Multicenter randomized 
controlled 
124 
 
22.6 ± 12.7 
 
3065 ± 4853  
 
 
- 
Kleemann T et al.12 
 
 
 
Observational Pre DRM 6617 
Post DRM 526 
 
26 (17–41)  
23 (13–49)  
 
3400 (1800–6400)  
800 (300–3700) 
- 
Blockhaus C et al.13 Observational Pre DRM 37 
Post DRM 15 
16.8 ± 8.8 
9.5 ± 3.1 
6208 ± 3314  
4342 ± 2073  
- 
Lehrmann H et al.14 Observational Pre DRM 2005: 52 
Post DRM 2015: 52 
53 (41–71) 
5 (4–6) 
4635 (3155–6357) 
185 (117–286) 
9.3 (6.4–13.4)  
0.4 (0.3–0.6) 
Lee JH et al.15 Retrospective Pre DRM 57 
Post DRM 76 
24.4 (17.5–34.9)  
15.1 (10.7–20.1) 
599.9 (371.4–1337.5) 
392.0 (289.7–591.4) 
1.1 (0.7–2.5) 
0.7 (0.6–1.1) 
Attanasio P et al.16 Observational Pre DRM 75 
Post DRM 75 
14.22 ± 4.47 
13.62 ± 7.11 
630.28 ± 550.96 
226.44 ± 277.44 
- 
Rubesch-Kütemeyer 
V et al.17 
Retrospective Pre DRM CB 50 
Post DRM CB 50 
18±6 
12±5 
4935±2094 
1555±1219 
9.8 
3.2 
Reissmann B et al.18 Retrospective Pre DRM CB 60 
Post DRM CB 60 
14 (11–19) 
10 (8–12) 
2168 (1355–3490)  
389 (285–550) 
- 
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TYPE OF 
PROCEDURE 
REFERENCE TYPE OF STUDY NUMBER OF PATIENTS FLUOROSCOPY TIME 
(min)* 
DAP 
(cGycm2)* 
EFFECTIVE DOSE 
(mSv)* 
VT/PVC 
Smith IR et al.2 Retrospective 97 17.4 (9.7-26.4) 2080 (1150-3150) 2.9 (1.6-4.4) 
Heidbuchel H et al.4 EHRA practical guide - - - 12.5 (3-≥45) 
SVT 
Smith IR et al.2 Retrospective AFl 498 
AVNRT 270 
AVRT 135 
AT 124 
16.8 (9.5-30.5) 
2.1 (1.3-4.5) 
23.8 (13.4-45.3) 
14.9 (7.7-28) 
1890 (1130-3530) 
260 (170-610) 
2690 (1600-5410) 
1770 (900-3510) 
- 
Rogers DP et al.3 Observational Pre DRM 214 
Post DRM 417 
- 2040 ± 2690 
800 ± 1030 
- 
1.24 
Heidbuchel H et al.4 EHRA practical guide - - - 4.4 (1.6-25) 
Lehrmann H et al.14 Observational AVNRT 187 8 (6–13) 158 (78–338) 0.4 (0.2–0.8) 
Casella M et al.19 Multicentre randomized Pre DRM 128 
Post DRM 134 
14.32 (9.08-22.43) 
0 (0-0.2) 
2036 (54–5297) 
278 (80–791) 
8.87 (3.67–22.01) 
0 (0–0.08) 
Giaccardi M et al.20 
 
Retrospective Pre DRM 144 
Post DRM 250 
19.32 ± 13.88 
0.23 ± 0.1  
10963.3 ± 10472.2 
283.4 ± 56.8 
- 
See J et al.21 Observational Pre DRM AVNRT 66 
Post DRM AVNRT 35 
20.3 ± 10.6  
6.8 ± 5.8  
1361.9 ± 976.9  
392.0 ± 462.5  
- 
CRT 
Butter C et al.22 Observational 104 20.3 ± 16 11100 ± 10100 - 
Morris M et al.23 Retrospective 1316 18.7 ± 0.3 2510 ± 1300 - 
Heidbuchel H et al.4 EHRA practical guide - - - 22 (2.2-95) 
Thibault B et al.24 Observational MG 60 
CONV 70 
6.5 (4.3-10.7) 
19.1 (10.2-25.3) 
769 (491-2182) 
2608 (1333-5345) 
- 
van Dijk JD et al.25 Retrospective Pre DRM 183 
Post DRM 230 
- 7210 ± 6000 
1780 ± 1740 
- 
PM/ICD 
Tsalafoutas IA et 
al.26 
Observational 55 6.6 1104 - 
Compagnone G et 
al.27 
Observational 68 7.5 2570 - 
Heidbuchel H et al.4 EHRA practical guide - - - 4 (1.4-17) 
van Dijk JD et al.25 Retrospective Pre DRM 408 
Post DRM 364 
- 1640 ± 1850  
520 ± 660 
- 
Attanasio P et al.28 
 
Retrospective Pre DRM 280 
Post DRM 304 
13 ± 15  
13 ± 15  
3792±5025 
1372±2659 
- 
EPS 
Pantos I et al.29 Retrospective 237 9 (0.1-258) 1450 3.2 (1.3-23.9) 
Smith IR et al.2 Retrospective 732 2.1 (1.3-3.3) 240 (150-390) 0.3 (0.2-0.5) 
Heidbuchel H et al.4 EHRA practical guide - - - 3.2 (1.3-23.9) 
* Values are expressed as mean ± standard deviation or median and interquartile range. 
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AF = atrial fibrillation; AFl = atrial flutter; AT = atrial tachycardia; AVNRT = atrio-ventricular nodal reentrant tachycardia; AVRT = atrio-
ventricular reentrant tachycardia; CB = cryoballoon; CONV = conventional; CRT = cardiac resynchronization therapy; DAP = dose area product; 
DRM = dose reduction maneuvers; EPS = electrophysiological study; ICD = implantable cardiac defibrillator; MG = MediGuideTM; PM = 
pacemaker; PVC = premature ventricular contractions; RF = radiofrequency; SVT = supraventricular tachycardia; VT = ventricular tachycardia. 
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